Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16271. [Epub ahead of print]

PMID:
31682002
2.

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Herrera AF, Goy A, Mehta A, Ramchandren R, Pagel JM, Svoboda J, Guan S, Hill JS, Kwei K, Liu EA, Phillips T.

Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25659. [Epub ahead of print]

PMID:
31621094
3.

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.

Vo P, Gooley TA, Rajendran JG, Fisher DR, Orozco JJ, Green DJ, Gopal AK, Haaf R, Nartea M, Storb R, Appelbaum FR, Press OW, Pagel JM, Sandmaier BM.

Haematologica. 2019 Oct 3. pii: haematol.2019.229492. doi: 10.3324/haematol.2019.229492. [Epub ahead of print]

4.

Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.

Patel K, Danilov AV, Pagel JM.

Blood. 2019 Nov 7;134(19):1573-1577. doi: 10.1182/blood.2019001795.

PMID:
31554637
5.

Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma.

Cassaday RD, Press OW, Pagel JM, Rajendran JG, Gooley TA, Fisher DR, Holmberg LA, Miyaoka RS, Sandmaier BM, Green DJ, Gopal AK.

Clin Cancer Res. 2019 Sep 3. doi: 10.1158/1078-0432.CCR-19-1567. [Epub ahead of print]

PMID:
31481510
6.

Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.

Patel K, Pagel JM.

Curr Hematol Malig Rep. 2019 Aug;14(4):292-301. doi: 10.1007/s11899-019-00525-9. Review.

PMID:
31203516
7.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

8.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC.

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

9.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
10.

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S.

J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17.

PMID:
30995176
11.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
12.

Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.

Patel K, Sudhir VS, Kabadi S, Huang JC, Porwal S, Thakkar K, Pagel JM.

J Oncol Pharm Pract. 2019 Dec;25(8):1897-1906. doi: 10.1177/1078155219827637. Epub 2019 Feb 5.

PMID:
30823852
13.

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ.

Blood. 2019 Feb 28;133(9):990-992. doi: 10.1182/blood-2018-06-857714. Epub 2018 Dec 28. No abstract available.

PMID:
30593446
14.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

15.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

16.

Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Pagel JM, West HJ.

JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989. No abstract available.

PMID:
28880983
17.

A Richter transformation PD-1 block party.

Pagel JM.

Blood. 2017 Jun 29;129(26):3397-3398. doi: 10.1182/blood-2017-05-781229. No abstract available.

PMID:
28663221
18.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

19.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC.

Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.

20.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

21.

Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.

Cowan AJ, Stevenson PA, Gooley TA, Frayo SL, Oliveira GR, Smith SD, Green DJ, Roden JE, Pagel JM, Wood BL, Press OW, Gopal AK.

Br J Haematol. 2017 Feb;176(4):583-590. doi: 10.1111/bjh.14451. Epub 2017 Jan 5.

22.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

23.

Neighborhood imbalances: overcoming MCL drug resistance.

Pagel JM.

Blood. 2016 Dec 15;128(24):2752-2753. No abstract available.

PMID:
27979866
24.

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U.

Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15.

25.

Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis - a single institution experience.

Shadman M, Hingorani S, Lanum SA, Pagel JM, Storb R, Maloney DG, Sandmaier BM.

Leuk Lymphoma. 2017 Mar;58(3):740-742. doi: 10.1080/10428194.2016.1211280. Epub 2016 Jul 25. No abstract available.

26.

Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?

Brown JR, Hallek MJ, Pagel JM.

Am Soc Clin Oncol Educ Book. 2016;35:e387-98. doi: 10.14694/EDBK_159018. Review.

27.

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Green DJ, Bensinger WI, Holmberg LA, Gooley T, Till BG, Budde LE, Pagel JM, Frayo SL, Roden JE, Hedin L, Press OW, Gopal AK.

Bone Marrow Transplant. 2016 Oct;51(10):1330-1336. doi: 10.1038/bmt.2016.123. Epub 2016 May 23.

28.

Discussion: Managing Risk When Using Idelalisib.

Coutre SE, Burger JA, Pagel JM.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 8):13. No abstract available.

PMID:
27168205
29.

Initiation of Treatment in Chronic Lymphocytic Leukemia.

Pagel JM.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 8):3-5. Review. No abstract available.

PMID:
27168202
30.

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR.

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.

31.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF.

N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.

32.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS, Hylarides MD, Frost SH, Mawad R, O'Donnell P, Sandmaier BM, Fuchs EJ, Luznik L, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17.

33.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.

Br J Haematol. 2016 Jan;172(2):238-45. doi: 10.1111/bjh.13829. Epub 2015 Nov 16.

PMID:
26568032
34.

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK.

Br J Haematol. 2015 Dec;171(5):788-97. doi: 10.1111/bjh.13773. Epub 2015 Oct 12.

35.

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK.

Ann Oncol. 2015 Nov;26(11):2323-8. doi: 10.1093/annonc/mdv364. Epub 2015 Sep 7.

36.

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.

Frost SH, Miller BW, Bäck TA, Santos EB, Hamlin DK, Knoblaugh SE, Frayo SL, Kenoyer AL, Storb R, Press OW, Wilbur DS, Pagel JM, Sandmaier BM.

J Nucl Med. 2015 Nov;56(11):1766-73. doi: 10.2967/jnumed.115.162388. Epub 2015 Sep 3.

37.

Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.

Cowan AJ, Frayo SL, Press OW, Palanca-Wessels MC, Pagel JM, Green DJ, Gopal AK.

Anticancer Drugs. 2015 Oct;26(9):974-83. doi: 10.1097/CAD.0000000000000274.

38.

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.

Shadman M, Gopal AK, Kammerer B, Becker PS, Maloney DG, Pender B, Shustov AR, Press OW, Pagel JM.

Leuk Lymphoma. 2016;57(3):572-6. doi: 10.3109/10428194.2015.1067701. Epub 2015 Aug 28.

39.

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur DS, Fisher DR, Orozco JJ, Press OW, Pagel JM, Sandmaier BM.

Med Phys. 2015 Jul;42(7):4094-105. doi: 10.1118/1.4921997.

40.

Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.

Loeb KR, Cherian S, Becker PS, Walter RB, Pagel JM, Abkowitz JL, Appelbaum FR, Wood BL, Estey EH.

Br J Haematol. 2016 Jan;172(1):134-6. doi: 10.1111/bjh.13465. Epub 2015 May 26. No abstract available.

PMID:
26010105
41.

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.

Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K, Dean C, Estey EH, Pagel JM.

Br J Haematol. 2015 Aug;170(3):349-55. doi: 10.1111/bjh.13437. Epub 2015 Apr 8.

PMID:
25854284
42.

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.

Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM, Bäck TA, Fisher DR, Press OW.

PLoS One. 2015 Mar 18;10(3):e0120561. doi: 10.1371/journal.pone.0120561. eCollection 2015.

43.

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ.

Blood. 2015 Apr 30;125(18):2779-85. doi: 10.1182/blood-2014-12-613570. Epub 2015 Mar 13.

44.

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR, Estey EH.

J Clin Oncol. 2015 Apr 10;33(11):1258-64. doi: 10.1200/JCO.2014.58.3518. Epub 2015 Mar 2.

PMID:
25732155
45.

Management of adverse events associated with idelalisib treatment: expert panel opinion.

Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD.

Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19. Review.

46.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.

Shadman M, Mawad R, Dean C, Chen TL, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS, Pagel JM, Estey EH.

Am J Hematol. 2015 Jun;90(6):483-6. doi: 10.1002/ajh.23981. Epub 2015 Feb 27.

47.

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR, Estey EH.

Leukemia. 2015 Aug;29(8):1779-80. doi: 10.1038/leu.2015.23. Epub 2015 Feb 4. No abstract available.

PMID:
25650090
48.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Bäck T, Sandmaier BM, Pagel JM, Press OW.

Blood. 2015 Mar 26;125(13):2111-9. doi: 10.1182/blood-2014-11-612770. Epub 2015 Jan 27.

49.

G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.

Am J Hematol. 2015 Apr;90(4):295-300. doi: 10.1002/ajh.23927. Epub 2015 Jan 30.

50.

Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.

Tong WG, Sandhu VK, Wood BL, Hendrie PC, Becker PS, Pagel JM, Walter RB, Estey EH.

Haematologica. 2015 Mar;100(3):e97-8. doi: 10.3324/haematol.2014.118422. Epub 2014 Dec 19. No abstract available.

Supplemental Content

Loading ...
Support Center